CStone says pralsetinib sales volume jumps nearly 500% after China NRDL listing

• CStone reported 2026 interim results, highlighting CS2009 Phase I/II updates through August with sustained safety and deeper efficacy signals.
• First-line NSCLC monotherapy at 30 mg/kg: ORR 70.8% in PD-L1 TPS ≥1%; ORR 100% in PD-L1 TPS ≥50%.
• Second-line NSCLC after IO-chemotherapy at 30 mg/kg: ORR 38.5%; mCRC later-line at 30 mg/kg: ORR 20%, DCR 93.3%.
• Pralsetinib in-market sales volume rose nearly 500% year over year in the seven months ended July 2026, following NRDL inclusion.
• Cash, cash equivalents, time deposits totaled RMB 1.56 billion as of June 30, 2026; first global Phase III CS2009 trials targeted by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310822PR_NEWS_USPR_____CN36909) on August 31, 2026, and is solely responsible for the information contained therein.